In this issue:
Effect of ambulatory oxygen on quality of life in fibrotic lung disease
A novel autotaxin inhibitor for treating IPF
Pirfenidone in the context of multiple disease progression events in IPF
Nintedanib + sildenafil in IPF
Australian patients’ experiences of IPF care
Safety of benzodiazepines and opioids in ILD
Nintedanib for systemic sclerosis-associated ILD
Quantitative CT-derived vessel metrics in IPF
Emphysematous changes in scleroderma-associated ILD
Please login below to download this issue (PDF)